CN1198818C - 具有释放生长激素特性的化合物 - Google Patents

具有释放生长激素特性的化合物 Download PDF

Info

Publication number
CN1198818C
CN1198818C CNB008151458A CN00815145A CN1198818C CN 1198818 C CN1198818 C CN 1198818C CN B008151458 A CNB008151458 A CN B008151458A CN 00815145 A CN00815145 A CN 00815145A CN 1198818 C CN1198818 C CN 1198818C
Authority
CN
China
Prior art keywords
compounds
growth hormone
acid
benzyl
tert
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB008151458A
Other languages
English (en)
Chinese (zh)
Other versions
CN1420878A (zh
Inventor
迈克尔·安克森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN1420878A publication Critical patent/CN1420878A/zh
Application granted granted Critical
Publication of CN1198818C publication Critical patent/CN1198818C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
CNB008151458A 1999-11-10 2000-11-10 具有释放生长激素特性的化合物 Expired - Lifetime CN1198818C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901618 1999-11-10
DKPA199901618 1999-11-10
US16710199P 1999-11-23 1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en) 1999-11-10 2000-11-10 Compound with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
CN1420878A CN1420878A (zh) 2003-05-28
CN1198818C true CN1198818C (zh) 2005-04-27

Family

ID=26065963

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008151458A Expired - Lifetime CN1198818C (zh) 1999-11-10 2000-11-10 具有释放生长激素特性的化合物

Country Status (23)

Country Link
US (1) US6576648B2 (enExample)
EP (1) EP1230236B1 (enExample)
JP (2) JP2003527338A (enExample)
KR (1) KR100907637B1 (enExample)
CN (1) CN1198818C (enExample)
AT (1) ATE280168T1 (enExample)
AU (1) AU782260B2 (enExample)
BR (1) BR0015407A (enExample)
CA (1) CA2387095C (enExample)
CZ (1) CZ301078B6 (enExample)
DE (1) DE60015173T2 (enExample)
DK (1) DK1230236T3 (enExample)
ES (1) ES2231279T3 (enExample)
HU (1) HU229445B1 (enExample)
IL (1) IL149049A0 (enExample)
MX (1) MXPA02004656A (enExample)
NO (1) NO323910B1 (enExample)
PL (1) PL199989B1 (enExample)
PT (1) PT1230236E (enExample)
RU (1) RU2272034C2 (enExample)
UA (1) UA73530C2 (enExample)
WO (1) WO2001034593A1 (enExample)
ZA (1) ZA200202757B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531769A (ja) * 2004-03-30 2007-11-08 サファイア セラピューティクス インコーポレイテッド 成長ホルモン分泌促進薬を使用したｃ−反応性蛋白質の低減方法
AU2005272074B2 (en) * 2004-06-29 2011-11-24 Albany Molecular Research, Inc. Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
US20130281701A1 (en) * 2004-06-29 2013-10-24 Helsinn Therapeutics (U.S.), Inc. Crystal forms of anamorelin
CN1976921B (zh) * 2004-06-29 2013-08-21 蓝宝石治疗公司 (3r)-1-(2-甲基丙氨酰-d-色氨酰)-3-(苯甲基)-3-哌啶羧酸1,2,2-三甲基酰肼的晶形
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
WO2008005268A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗（美国）有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
US8664267B2 (en) * 2007-04-12 2014-03-04 Academic Pharmaceuticals Incorporated Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
MX2010008740A (es) 2008-02-08 2010-08-30 Zeria Pharm Co Ltd Derivado de 3,8-diaminotetrahidroquinolina.
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) * 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
US20150265680A1 (en) 2012-10-24 2015-09-24 Daiichi Sankyo Company, Limited Therapeutic agent for amyotrophic lateral sclerosis
CN106187865A (zh) * 2016-07-08 2016-12-07 武汉工程大学 (r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108129357B (zh) * 2016-12-01 2021-12-21 上海医药工业研究院 阿拉莫林中间体的制备方法
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
US20220323430A1 (en) * 2019-08-30 2022-10-13 Helsinn Healthcare Sa Methods of manufacturing anamorelin tablets having improved stability
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
WO1989010933A1 (en) 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
KR960705808A (ko) * 1993-11-09 1996-11-08 조셉 에프. 디프리마 성장 호르몬의 방출을 촉진시키는 피페리딘, 피롤리딘 및 헥사하이드로-1H-아제핀(Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone)
EP0730578A4 (en) 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING INDOLYL GROUPS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONES
US5721250A (en) 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JP4425992B2 (ja) * 1996-07-22 2010-03-03 サファイア セラピューティクス，インコーポレイティド 成長ホルモン放出特性を有する化合物
WO1999036431A1 (en) * 1998-01-16 1999-07-22 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2329881C (en) * 1998-05-11 2010-03-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107001323A (zh) * 2015-10-20 2017-08-01 江苏恒瑞医药股份有限公司 一种阿拉莫林的结晶形式及其制备方法

Also Published As

Publication number Publication date
NO323910B1 (no) 2007-07-16
AU1269401A (en) 2001-06-06
KR20020059694A (ko) 2002-07-13
EP1230236B1 (en) 2004-10-20
CZ20021587A3 (cs) 2002-09-11
CA2387095C (en) 2011-01-11
ES2231279T3 (es) 2005-05-16
HUP0203844A3 (en) 2004-07-28
NO20022200L (no) 2002-05-08
PL199989B1 (pl) 2008-11-28
JP2009062369A (ja) 2009-03-26
CZ301078B6 (cs) 2009-10-29
BR0015407A (pt) 2002-07-02
UA73530C2 (uk) 2005-08-15
US6576648B2 (en) 2003-06-10
JP5053960B2 (ja) 2012-10-24
AU782260B2 (en) 2005-07-14
WO2001034593A1 (en) 2001-05-17
EP1230236A1 (en) 2002-08-14
US20010041720A1 (en) 2001-11-15
IL149049A0 (en) 2002-11-10
CN1420878A (zh) 2003-05-28
JP2003527338A (ja) 2003-09-16
PT1230236E (pt) 2005-03-31
HU229445B1 (en) 2013-12-30
ZA200202757B (en) 2003-02-26
ATE280168T1 (de) 2004-11-15
HUP0203844A2 (hu) 2003-03-28
CA2387095A1 (en) 2001-05-17
MXPA02004656A (es) 2002-09-02
NO20022200D0 (no) 2002-05-08
PL356993A1 (en) 2004-07-12
RU2272034C2 (ru) 2006-03-20
DE60015173D1 (de) 2004-11-25
DE60015173T2 (de) 2005-12-08
KR100907637B1 (ko) 2009-07-14
DK1230236T3 (da) 2005-02-21

Similar Documents

Publication Publication Date Title
CN1198818C (zh) 具有释放生长激素特性的化合物
CN1121387C (zh) 3,4,4－三取代的哌啶基－n－烷基羧酸盐类化合物的制备及中间体
JP4938708B2 (ja) 成長ホルモン放出特性を有する化合物
CN1520293A (zh) 作为抗糖尿病药物的3-氟-吡咯烷类
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1323307A (zh) 1h－咪唑并吡啶衍生物
CN1040985C (zh) 苯并氮杂䓬类化合物的制备方法
CN1353701A (zh) 用作类胰蛋白酶抑制剂的肽基杂环酮类化合物
JP2003527338A5 (enExample)
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1956978A (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4－(5－氨基甲基－2－氟－苯基) －哌啶－1－基] －(4－溴－3－甲基－5－丙氧基－噻吩－2－基)-甲酮盐酸盐
RU2298547C2 (ru) Соединения и фармацевтическая композиция, обладающие свойствами высвобождения гормона роста, способ стимуляции выделения гормона роста из гипофиза млекопитающего
CN1347325A (zh) 用作生长激素促分泌剂的新酰胺衍生物
CN1784398A (zh) 作为搔痒治疗药有效的4－(2－呋喃甲酰基)氨基哌啶类化合物
CN1198816C (zh) 新的法尼基蛋白转移酶抑制剂
CN1325408A (zh) 具有生长激素释放特性的化合物
HK1062526A (en) Tripeptidyl peptidase inhibitors
UA72462C2 (en) Compounds with properties of releasing the growth hormone and a pharmaceutical composition based thereon
MXPA00012489A (en) Compounds with growth hormone releasing properties

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050427